---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-013017"
form_type: "8-K"
ticker: "CODX"
cik: "0001692415"
company_name: "Co-Diagnostics, Inc."
filed_at: "2022-05-12T23:59:59+00:00"
generated_at: "2026-06-25T18:45:29.739234+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Co-Diagnostics reports Q1 revenue $22.7M, net income $11.7M ($0.34 EPS); no guidance given

## Summary
- Q1 revenue $22.7M, record first quarter; net income $11.7M ($0.34 diluted EPS) vs $7.9M a year ago.
- Gross profit $19.4M (85.5% margin); operating income $9.8M down from $10.3M on higher R&D.
- Cash, equivalents, and marketable securities $97.4M, up $7.5M from Dec 2021.
- Co-Dx PCR home testing platform progressing toward FDA submission later this year.
- No quarterly guidance provided due to diminished COVID-19 test sales forecasting ability.

## SEC filing metadata
- accession: 0001493152-22-013017
- form_type: 8-K
- ticker: CODX
- cik: 0001692415
- company_name: Co-Diagnostics, Inc.
- filed_at: 2022-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1692415/000149315222013017/0001493152-22-013017-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1692415/000149315222013017/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-013017
- JSON: https://secwatch.observer/filing/0001493152-22-013017.json
- Plain text: https://secwatch.observer/filing/0001493152-22-013017.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.